Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenocortical Carcinoma - Pipeline Review, H1 2020, provides an overview of the Adrenocortical Carcinoma (Oncology) pipeline landscape.
Adrenal cortex cancer (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. Predisposing factors include female, hereditary disease that affects the adrenal glands, age and smoking. Symptoms include high blood sugar and pressure, muscle weakness in the legs, excessive weight gain in chest and abdomen, early signs of puberty in children, increased facial and body hair, particularly in females and deepened voice in females.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adrenocortical Carcinoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Adrenocortical Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Discovery stages are 4, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Adrenocortical Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenocortical Carcinoma - Pipeline Review, H1 2020, provides an overview of the Adrenocortical Carcinoma (Oncology) pipeline landscape.
Adrenal cortex cancer (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. Predisposing factors include female, hereditary disease that affects the adrenal glands, age and smoking. Symptoms include high blood sugar and pressure, muscle weakness in the legs, excessive weight gain in chest and abdomen, early signs of puberty in children, increased facial and body hair, particularly in females and deepened voice in females.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adrenocortical Carcinoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Adrenocortical Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Discovery stages are 4, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Adrenocortical Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Adrenocortical Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Adrenocortical Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Adrenocortical Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Adrenocortical Carcinoma (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Adrenocortical Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Development
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Assessment
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Companies Involved in Therapeutics Development
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Drug Profiles
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Product Development Milestones
Appendix
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Development
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Assessment
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Companies Involved in Therapeutics Development
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Drug Profiles
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Bristol-Myers Squibb Co, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Exelixis Inc, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Infinity Pharmaceuticals Inc, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Merck & Co Inc, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Merck KGaA, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Millendo Therapeutics Inc, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Orphagen Pharmaceuticals Inc, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Seneca Therapeutics Inc, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Trovagene Inc, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Y-mAbs Therapeutics Inc, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products, H1 2020
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Bristol-Myers Squibb Co, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Exelixis Inc, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Infinity Pharmaceuticals Inc, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Merck & Co Inc, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Merck KGaA, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Millendo Therapeutics Inc, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Orphagen Pharmaceuticals Inc, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Seneca Therapeutics Inc, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Trovagene Inc, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Y-mAbs Therapeutics Inc, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects, H1 2020
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
Bristol-Myers Squibb Co
Exelixis Inc
Infinity Pharmaceuticals Inc
Merck & Co Inc
Merck KGaA
Millendo Therapeutics Inc
Orphagen Pharmaceuticals Inc
Seneca Therapeutics Inc
Trovagene Inc
Y-mAbs Therapeutics Inc
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
Bristol-Myers Squibb Co
Exelixis Inc
Infinity Pharmaceuticals Inc
Merck & Co Inc
Merck KGaA
Millendo Therapeutics Inc
Orphagen Pharmaceuticals Inc
Seneca Therapeutics Inc
Trovagene Inc
Y-mAbs Therapeutics Inc
